在扩展阶段的小细胞肺癌中,基于免疫和向治疗的进展
Xiao-Tong Zou1,2, Jie Huang2, Hao Sun2
1Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
Therapeutic advances in medical oncology
|July 29, 2025
概括
免疫检查点抑制剂 (ICI) 提高了扩散阶段小细胞肺癌 (SCLC) 的存活率. 对新型免疫疗法组合和点的进一步研究对于提高SCLC治疗结果至关重要.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 免疫疗法,特别是免疫检查点抑制剂 (ICI),是现代癌症治疗的重要组成部分.
- 像阿特佐利祖马布和杜尔瓦卢马布这样的ICI已经证明了广泛阶段小细胞肺癌 (SCLC) 联合化疗的有效性,建立了改善整体存活率的新治疗标准.
研究的目的:
- 审查免疫疗法在小细胞肺癌 (SCLC) 中的当前作用和未来方向.
- 探索新兴的组合策略和新型治疗药物,超出目前SCLC的ICI疗法.
主要方法:
- 对临床试验的文献综述和对SCLC免疫治疗的研究.
- 对影响SCLCICI敏感性的分子亚型和生物标志物的分析.
- 评估新型免疫治疗方法,包括抗体药物合物和基于细胞的疗法.
主要成果:
- ICI已经显著推进了SCLC治疗,提供超过一年的生存益处.
- 目前ICI的益处有限,需要探索组合疗法 (例如,用放射治疗,抗血管原剂).
- 新兴的疗法,如抗体药物合物,双特异性T细胞参与剂和CAR T细胞疗法对SCLC有很大的前景.
结论:
- 虽然ICI代表了SCLC治疗的突破,但对组合策略的进一步优化至关重要.
- 了解SCLC分子亚型和生物标志物是个性化免疫治疗的关键.
- 新药的开发和新点的探索为改善SCLC免疫治疗结果提供了未来的希望.
更多相关视频
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.6K
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
10.7K
相关概念视频
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
01:27Tumor Immunotherapy
662
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
662
02:50Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K